Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof
AssigneeUniversite Laval
InventorsMichel Fortier, Pierre Chapdelaine, Eva Bresson, Eric Madore
Life of this patent
Estimating the term…
Abstract
AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH2 into PGF2α. AKR1B1 as a therapeutic target, and method for modulating its expression and activity are provided. Methods for regulating the expression and activity of PGF2α are also provided.
Claims23
The method of claim 55, wherein said modulating decreases the PGFS activity in the subject and the modulator is an inhibitor of the PGF synthase activity of AKR1B1 (EC 1.1.1.21)
The method of claim 57, wherein said modulating decreases the level of PGF2α in the subject, and the modulator is an inhibitor of the PGF synthase activity of AKR1B1 (EC 1.1.1.21).
The method of claim 58, wherein the altered PGF2α levels or activity are increased in the subject and the modulator is an inhibitor of the PGF synthase activity of AKR1B1 (EC 1.1.1.21).
The method of claim 55, wherein said modulating increases the PGFS activity in the subject and the modulator is an activator of the PGF synthase activity of AKR1B1.
The method of claim 57, wherein said modulating increases the level of PGF2α in the subject and the modulator is an activator of the PGF synthase activity of AKR1B1.
The method of claim 58, wherein the altered PGF2α levels or activity are decreased in the subject and the modulator is an activator of the PGF synthase activity of AKR1B1.
19-54. (canceled)
A method for modulating PGFS activity in a subject, said method comprising the step of administering a modulator of the PGF synthase activity of AKR1B1 (EC 1.1.1.21) to said subject.
A method for modulating the level of PGF2α in a subject, said method comprising the step of administering a modulator of the PGF synthase activity of AKR1B1 to said subject.
A method for treating or preventing a condition associated with altered PGF2α levels or activity in a subject, said method comprising the step of administering a modulator of PGF synthase activity of AKR1B1 (EC 1.1.1.21) to said subject.
Dependencies are inferred from the claim text.